IMNM - יחס חוב להיוון בספרים Immunome Inc

Immunome, Inc. (IMNM) price action reflects a current level of 0.01. The business leverages advanced AI technologies to discover antibodies for combating tumors. The company's stability is underpinned by US laboratories and successful immune response tests. Currently, Immunome, Inc. (IMNM) is actively acquiring promising molecules through M&A transactions to accelerate the renewal of its drug portfolio.

This indicator measures the debt load level by comparing total liabilities to equity to assess financial stability and default risks. By analyzing the total debt-to-equity ratio, an investor can determine the margin of safety for Immunome, Inc. (IMNM), which is critical when financing the costly development of antibodies and ADC drugs prior to their full market launch.